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Molecular epidemiology studies have identified HLA-B*58:01 as a protective HIV allele. However, not all
B*58:01-expressing persons exhibit slow HIV disease progression. We followed six HLA-B*58:01-positive, HIV
subtype C-infected individuals for up to 31 months from the onset of infection and observed substantial
variability in their clinical progression despite comparable total breadths of T cell responses. We therefore
investigated additional immunological and virological factors that could explain their different disease tra-
jectories. Cytotoxic T-lymphocyte (CTL) responses during acute infection predominantly targeted the TW10
and KF9 epitopes in p24Gag and Nef, respectively. Failure to target the TW10 epitope in one B*58:01-positive
individual was associated with low CD4 counts and rapid disease progression. Among those targeting TW10,
escape mutations arose within 2 to 15 weeks of infection. Rapid escape was associated with preexisting
compensatory mutations in the transmitted viruses, which were present at a high frequency (69%) in the study
population. At 1 year postinfection, B*58:01-positive individuals who targeted and developed escape mutations
in the TW10 epitope (n  5) retained significantly higher CD4 counts (P  0.04), but not lower viral loads,
than non-B*58:01-positive individuals (n  17). The high population-level frequency of these compensatory
mutations may be limiting the protective effect of the B*58:01 allele.
HLA-B*57 and -B*58:01 are overrepresented among elite
and viremic controllers of HIV-1 subtype C infections (8, 18,
24, 26); however, the specific mechanism(s) underlying these
protective effects remains incompletely understood. Strong
cytotoxic T-lymphocyte (CTL) responses targeting multiple
epitopes in the conserved p24 region of Gag during the critical
acute/early stage of disease likely contribute to viral control in
these individuals (2, 18, 29). Moreover, CTL-driven selection
of viral escape mutations associated with substantial costs to
viral protein function and replication capacity is also likely a
major contributor to better control of viremia in individuals
carrying particular HLA alleles (4, 9, 19, 21).
One of the most extensively studied HLA-B*57/B*58:01-
restricted escape mutations is the T242N mutation within the
immunodominant TW10 epitope in p24Gag. In acute subtype B
and subtype C infection, TW10 ranks among the earliest tar-
geted epitopes (5, 15); however, the T242N escape mutation is
generally rapidly selected. In vitro studies have directly shown
that the T242N mutation incurs a fitness cost (4, 8, 21); how-
ever, compensatory mutations upstream and downstream of
the epitope have been reported to partially rescue these
defects (4, 19). Recently, it has been observed that HLA-
B*57- and -B*58:01-positive elite controllers select for rare
CTL escape variants within TW10 that are associated with
severe defects in viral replication, supporting the role of
immune-driven HIV attenuation as an important correlate
of the controller phenotype (24).
Although HLA-B*58:01 is a “protective” allele, not all B*58:
01-expressing persons exhibit slow HIV disease progression.
Here we investigate the immunological (i.e., CTL responses)
and viral (i.e., CTL escape mutations) correlates of differential
disease progression in six HIV-1 subtype C-infected HLA-
B*58:01-positive individuals.
MATERIALS AND METHODS
Study subjects. Individuals involved in this study were part of the CAPRISA
002 cohort investigating the role of viral and immunological factors in HIV
progression during acute/early HIV-1 subtype C infection (7, 32). The cohort
includes high-risk HIV-negative women monitored monthly for recent HIV-1
infection using two HIV-1 rapid antibody tests and PCR (Roche Amplicor v1.5).
HIV-1 infection was confirmed by enzyme immunoassay (EIA). Women were
enrolled within 3 months of infection from both the HIV-negative cohort and
other seroincident cohorts in Durban, South Africa. The timing of infection was
estimated either to be at the midpoint between the last HIV-1-negative test and
the first antibody-positive test or to be 14 days during which individuals were
PCR positive but antibody negative. Samples were collected at enrollment,
weekly for 3 weeks, fortnightly until 3 months, monthly until a year, and quarterly
thereafter. CD4 T cell counts were assessed using a FACSCalibur flow cytom-
eter, and viral loads were measured using a Cobas Amplicor HIV-1 Monitor
Test, v1.5 (Roche Diagnostics). Plasma collected in EDTA was stored at 70°C
until use. Written informed consent was obtained from all participants. This
study received ethical approval from the University of Kwa-Zulu Natal, the
University of the Witwatersrand, and the University of Cape Town. A total of 36
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individuals from the cohort who had reached 12 months postinfection were
included in this study, of which 24 were part of a study described previously (7).
RNA isolation, reverse transcription-PCR (RT-PCR), and viral sequencing.
Viral sequencing was carried out as previously described (7). RNA isolated from
plasma samples using the Magna-Pure Compact Nucleic Acid Extractor (Roche)
was reverse transcribed using the Invitrogen Thermoscript reverse transcription
kit (Invitrogen) and the primers Gag D reverse (5-AAT TCC TCC TAT CAT
TTT TGG-3; HXB2 positions 2382 to 2402) for gag and Nef O reverse (5-AGG
CAA GCT TTA TTG AGG-3; HXB2 positions 9608 to 9625) for nef. Limiting
dilution nested PCR was carried out by serial endpoint dilution of the cDNA
(27). The first-round PCR primers for gag amplification were Gag D forward
(5-TCT CTA GCA GTG GCG CCC G-3; HXB positions 626 to 644) and Gag
D reverse. The second-round PCR primers were Gag A forward (5-CTC TCG
ACG CAG GAC TCG GCT T-3; HXB2 positions 683 to 704) and Gag C
reverse (5-TCT TCT AAT ACT GTA TCA TCT GC-3; HXB2 positions 2334
to 2356). For nef, the first-round PCR primers were SQ15FC (5-GAG AGC
GGT GGA ACT TCT-3; HXB2 positions 8561 to 8578) and Nef O reverse. The
second-round PCR primers were Nef forward (5-CCT AGA AGA ATA AGA
CAG GGC TT-3; HXB2 positions 8754 to 8776) and Nef reverse (5-CCT GGA
ACG CCC CAG TGG-3; HXB2 positions 9443 to 9461). PCR products were
either directly sequenced or cloned using the pGEM-T Easy vector system
(Promega). Sequencing was carried out using an ABI Prism dye terminator
cycle-sequencing kit (Applied Biosystems) and the primers Gag A forward, Gag
A reverse (5-ACA TGG GTA TCA CTT CTG GGC T-3; HXB2 positions 1282
to 1303), Gag B forward (5-CCA TAT CAC CTA GAA CTT TGA AT-3;
HXB2 positions 1226 to 1246), Gag B reverse (5-CTC CCT GAC ATG CTG
TCA TCA T-3; HXB2 positions 1825 to 1846), Gag C forward (5-CCT TGT
TGG TCC AAA ATG CGA-3; HXB positions 1748 to 1768), and Gag C reverse
for Gag sequencing. The primers Nef forward and Nef reverse were used for Nef
sequencing. Sequences were assembled using ChromasPro (Technelysium, Aus-
tralia) and aligned using ClustalW (with default settings [31]).
HLA typing. High-resolution (four-digit) HLA typing was performed on all
participants. DNA was extracted from either peripheral blood mononuclear cells
(PBMCs) or granulocytes using the Pel-Freez DNA isolation kit (Pel-Freez).
HLA-A, -B, and -C typing was performed by sequencing of exons 2, 3, and 4
using Atria HLA-AlleleSeqr kits (Abbott) or HLA-SBTexcellerator kits
(Qiagen) and Assign-SBT v3.5 software (Conexio Genomics). Any ambiguities
resulting from either polymorphisms outside the sequenced exons or identical
heterozygote combinations were resolved using sequence-specific primers or
resolved statistically using the algorithm developed for this purpose (20).
IFN- ELISpot assay. PBMCs were prepared and screened for HIV-1-specific
T cell responses across the entire HIV-1 clade C proteome by gamma interferon
(IFN-) enzyme-linked immunospot (ELISpot) assay (22). For our analyses, we
focused on Gag and Nef because these proteins have been a key feature in
candidate CTL-based vaccines and are the most dominant targeted proteins in
HIV. T cell responses were either determined using a deconvoluted pool matrix
approach or confirmed using individual peptides. The epitopes within peptides
showing responses were delineated using published epitope sequences in the Los
Alamos HIV database (www.hiv.lanl.gov).
Statistical analyses. Wilcoxon rank-sum tests were used to compare viral loads
and CD4 counts. Fisher’s exact test was used to compare differences in fre-
quencies of compensatory mutations between sequences from the study cohort
and reference sequences. Statistical tests were implemented in GraphPad Prism
5.0 (GraphPad Software, Inc.).
Nucleotide sequence accession numbers. Nucleotide sequences determined in
this work were submitted to GenBank under accession numbers EU347404 to
EU347714 and JF704235 to JF705197.
RESULTS
The CAPRISA 002 study follows high-risk HIV-negative
individuals who are subsequently enrolled into an acute cohort
upon HIV infection. At the time of this study, 36 enrollees had
reached 1 year postinfection. Of these, six possessed the HLA-
B*58:01 allele while none had the closely related HLA-B*57
allele (14, 18). To control for fluctuations, viral load and CD4
counts at set point (12 months postinfection) were calculated
as the mean of three measurements taken at time points closest
to 12 months postinfection (range, 9 to 16 months). The me-
dian log viral load and CD4 count for the 36 participants at
12 months postinfection were 4.60 copies ml1 and 408 cells
l1, respectively (see Table S1 in the supplemental material).
There was no significant difference in viral load between the
B*58:01-positive participants (n  6) and non-B*58:01-posi-
tive participants (n  30) at 12 months postinfection (median
log viral load, 4.77 versus 4.65 copies ml1, respectively; P 
0.43). However, B*58:01-positive participants tended to have
higher CD4 T cell counts than non-B*58:01-positive partici-
pants (median, 600 versus 430 cells l1, respectively; P 
0.13; data not shown).
Early evolution in p24Gag is characterized by escape muta-
tions in the B*58:01-restricted TW10 epitope. Several studies
have attributed viremia control in HLA-B*57- and B*58:01-
expressing persons to their ability to target conserved epitopes
such as ISW9, KF11, and TW10 in p24Gag (1, 2). Escape
mutations in these epitopes have been shown to impair viral
replication (3, 4, 9, 30). In order to determine the impact of
immune pressure on the p24Gag region, we monitored viral gag
and nef evolution in the six HLA-B*58:01-positive participants
from infection until up to 31.4 months postinfection.
Escape mutations arose in the TW10 epitope in four of the
six individuals within 3.4 months postinfection, with the earliest
variation in the epitope being detected only 2 weeks postin-
fection (CAP239; Fig. 1). At this time point, this individual
(CAP239) was antibody negative but HIV RNA positive.
Emergence of the T242N mutation was often preceded by
variation at other sites within the epitope. This variation oc-
curred at six sites within the epitope at positions 3, 4, 5, 7, 8,
and 9 (T242, L243, Q244, Q246, I247, and A248, respectively).
Whereas in four individuals (CAP217, CAP229, CAP268, and
CAP270) the earliest sampled viruses had only the wild-type
TW10 sequence (TSTLQEQIAW), in the other two individu-
als (CAP239 and CAP274) the earliest sampled viruses carried
a mixture of wild-type and mutant TW10 sequences (Fig. 1).
The presence of variation at this earliest time point suggests
that escape from TW10-specific CTL responses occurred very
early during infection, although transmission of the escape
variant cannot be ruled out. Following its emergence, T242N
rapidly took over the population within the infected host: time
to fixation ranged from 1.2 (in individual CAP239) to 6.2 (in
individual CAP217) months from its first detection.
IFN- production by T cells in response to the TW10
epitope was investigated in the six B*58:01-positive partici-
pants using ELISpot assays. Three of four individuals harbor-
ing viruses that evolved escape mutations in the TW10 epitope
displayed a reduction in TW10-specific ELISpot responses fol-
lowing escape (Fig. 1). The fourth individual (CAP274), whose
virus harbored a 22%/78% mixture of the T242 and N242
polymorphisms at the earliest time point (2.4 months postin-
fection), had no detectable responses to TW10, suggesting that
an earlier transient CTL response to TW10 may have already
waned by the time the ELISpot assay was performed. In the
two individuals where CTL escape was not identified, CAP268
and CAP270, only CAP268 had detectable ELISpot responses
to TW10. In this individual, responses were 518 spot-forming
units (SFU)/106 PBMCs at 1.8 months postinfection, which
strengthened to 2,523 SFU/106 PBMCs by 5.5 months postin-
fection. Interestingly, the virus infecting CAP268 carried the
HLA-B*58:01-associated M250I mutation previously associated
with reduced frequency of escape in TW10 (21), suggesting that
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mutational antagonism by the M250I mutation prevented escape
within TW10. CAP270, the other individual whose virus did not
exhibit escape in TW10, did not respond to this epitope.
Disease progression in HLA-B*58:01-positive individuals is
influenced by immune targeting of TW10 and escape muta-
tions at T242. Viral load and CD4 cell count trajectories of
the six HLA-B*58:01-positive study participants were analyzed
to determine the impact of (i) TW10 targeting and CTL escape
through mutation at T242, (ii) TW10 targeting in the absence
of CTL escape at T242, and (iii) an absence of both TW10
targeting and CTL escape at T242. The four HLA-B*58:01-
positive individuals who targeted the TW10 epitope and whose
virus subsequently escaped this response (CAP217, CAP229,
CAP239, and CAP274) displayed moderate viral loads
(Fig. 2A). CAP268, the individual who displayed TW10-
specific ELISpot responses but who did not develop T242N,
had the lowest viral load (Fig. 2A). CAP270, the individual
who did not respond to TW10 (and consequently did select
FIG. 1. Alignment of TW10 epitope sequences (sequence underlined) and their flanking residues (one on either side) showing changes in the six
HLA-B*58:01-positive study participants over time. The relative frequencies of variants carrying the respective mutations are indicated along with the
ELISpot responses of the study participants from which the sequences were derived. Gray highlighting indicates different sampling time points.
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T242N), had a high viral load (Fig. 2A) and the lowest CD4
counts overall (Fig. 2B). CAP268, the individual who re-
sponded to TW10 but whose infecting viruses did not develop
the T242N mutation, had moderate CD4 T cell counts (Fig.
2B), while the four individuals (CAP217, CAP229, CAP239,
and CAP274) who responded to the epitope and harbored
viruses that developed the T242N mutation had moderate to
high CD4 counts (Fig. 2B).
These data suggest that CTL targeting of TW10 and the
subsequent accumulation of escape mutations in the epitope
may play an important role in disease progression. We show
here that events during acute and early subtype C infections,
such as the T242N escape mutation, are associated with the
preservation of CD4 counts, an association which may have
long term-benefits for the infected individuals.
Immune responses targeting p24 influence disease progres-
sion. We used IFN- ELISpot assays to assess whether differ-
ences in disease progression observed in the six HLA-B*58:01-
positive individuals correlated with the breadth and specificity of
their T cell responses. All six HLA-B*58:01-positive individu-
als responded to at least six epitopes (range, 6 to 10) across the
HIV-1 proteome (Table 1); between 2 and 4 of these repre-
sented previously described B*58:01-restricted immunodomi-
nant epitopes (2) (see Table S2 in the supplemental material).
FIG. 2. Viral load (A) and CD4 count (B) trajectories of the six HLA-B*58:01-positive study participants, including those infected with viruses
that escaped an active TW10-targeted CTL response via the T242N mutation (black), the study participant infected with viruses carrying the
wild-type TW10 sequence and who did not mount a detectable response to the epitope (red), and the study participant who responded to TW10
but whose infecting viruses did not accumulate escape mutations in the epitope (blue).
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Overall, 23 of the 43 (53%) responses detected by ELISpot
assay were likely restricted by HLA-B*58:01. Besides TW10-
specific responses and escape mutations within this epitope, no
other common responses or mutational patterns that could
explain the observed differences in disease progression were
observed (data not shown). However, it is noteworthy that the
individual displaying the best control of virus replication
(CAP268) responded to both the TW10 and KF11 epitopes in
p24Gag. No potential escape mutations were observed in KF11
in this participant. None of the other HLA-B*58:01-positive
individuals recognized KF11. Also interesting is the fact that
CAP270, the individual who exhibited the least favorable clin-
ical profile, completely lacked HLA-B*58:01-restricted re-
sponses in p24. The sole anti-p24 response detected in this
individual was directed at the HLA-B*08:01-restricted DL9
(DCKTILRAL) epitope. In chronic subtype C infection, a
weak association has been reported between HLA-B*08:01
and higher viremia (17).
No HLA enrichment associated with differential disease
progression. Certain HLA alleles, particularly those encoded
by HLA-B, are associated with rates of HIV disease progres-
sion (12, 17). We sought to determine whether other HLA
alleles besides HLA-B*58:01 could have contributed to the
disease progression patterns observed in the B*58:01-positive
TABLE 1. IFN- ELISpot responses of the six HLA-B*58:01-positive study participantsa
a Shown in blue are the confirmed single peptide responses. In black are the unconfirmed responsive peptides containing known
epitopes. In green are predicted epitopes based on HLA binding motifs. The epitopes are underlined (bold). The unconfirmed
peptides were predicted by pool matrix deconvolution. *, no known or predicted epitope.
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individuals. In addition to HLA-B*58:01, two of the six indi-
viduals (CAP239 and CAP274) also expressed B*42:01, an
allele associated with modest protective effects in subtype C
infection (17) (Table 2). The remaining individuals did not
express protective HLA-B alleles other than B*58:01. The
B*15:03 allele expressed by CAP217 (an individual displaying
intermediate viremia) and the B*08:01 allele expressed by
CAP270 (who was the most viremic of the HLA-B*58:01-
positive individuals) are both associated with poorer-than-
average control of virus replication during HIV infection (17).
It is conceivable, therefore, that the HLA-B*42:01, -B*15:03,
or -B*08:01 allele occurring in tandem with the HLA-B*58:01
allele may have contributed at least partially to various pat-
terns of disease progression observed within the HLA-B*58:
01-positive individuals. HLA homozygosity has previously been
associated with rapid HIV disease progression (6). One B*58:
01-positive patient in this cohort (CAP229) was homozygous at
the HLA-A, -B, and -C loci (Table 2) but did not show signif-
icantly higher viral loads or lower CD4 counts than other
B*58:01-positive individuals (Fig. 2), suggesting that in this
case at least, HLA homozygosity did not have a substantial
impact on disease progression.
Additional CTL escape predominantly occurred in the Nef
KF9 epitope. Next, we analyzed evolution within other immu-
noreactive epitopes in Gag and Nef. Four of six studied indi-
viduals (CAP217, CAP229, CAP239, and CAP270) also exhib-
ited escape in the Nef KF9 epitope (Fig. 3). Viruses from the
remaining two individuals already harbored KF9 escape mu-
tations at the time of enrollment (data not shown), indicating
very early escape or transmission of the escape variant. Fur-
thermore, potential escape mutations were also detected in
the HLA-B*42:01-restricted p17 Gag RY10 epitope (in both
CAP239 and CAP274), in the HLA-B*07:02-restricted Nef
RM9 epitope (in CAP268), in the HLA-A*30:02-restricted p17
Gag SL9 epitope (in CAP270), and in the HLA-B*08:01-re-
stricted Nef WI8 epitope (in CAP270). These data suggest that
other CTL escape mutations besides those occurring in the
Gag p27 TW10 epitope may have additionally contributed to
differences in disease progression observed in the six HLA-
B*58:01-positive individuals.
HLA-B*58:01 immune responses targeting TW10 and those
targeting T242N escape are both associated with improved
disease progression. We next wished to investigate the impact
of T cell responses to TW10, and escape within this epitope, on
markers of disease progression in HLA-B*58:01-negative
compared to B*5801-negative individuals. Previously pub-
lished data indicate that HLA-B*57/B*58:01-negative individ-
uals acquiring HIV harboring “signature” HLA-B*57- or
-B*58:01-associated escape mutations A146X and T242N ex-
hibit lower viral loads and higher CD4 counts than do indi-
viduals infected with viruses not harboring these substitutions
(7, 13, 30); therefore, we excluded 13 HLA-B*57- and -B*58:
01-negative study participants infected with viruses carrying
either A146X (X  P or S) or T242X (X  N or S) mutations
from our subsequent analyses.
A comparison of CD4 counts and viral loads of the B*58:
01-positive (n  6) and -negative (n  17) individuals at 12
months postinfection revealed no significant differences be-
tween these two groups (median CD4 counts, 600 versus 382
[P  0.09], respectively, and median viral load, 4.77 versus 4.69
[P  0.81], respectively). However, the B*58:01-positive indi-
viduals whose viruses developed the T242N mutation (n  4)
had significantly higher CD4 counts than did B*58:01-nega-
tive participants whose viruses did not carry the A146X and
T242X (n  17) mutations (P  0.04) (Fig. 4A). The viral loads
of these four individuals, however, did not significantly differ
from those of the control group (P  0.50) (Fig. 4B). Com-
parison of CD4 counts between the five B*58:01-positive
individuals with detectable TW10 responses and the 17 HLA-
B*58:01-negative individuals revealed significantly higher CD4
counts (P  0.04) (Fig. 4C) but no differences in viral load
(P  0.88) (Fig. 4D) between the former and latter groups,
respectively. We also analyzed clinical markers of disease pro-
gression at 3 years postinfection. At this time, six participants
(one B*58:01-positive participant, CAP270, and five B*58:01-
negative participants) had left the study due to initiation of
antiretroviral treatment. We observed a similar trend of higher
CD4 counts in HLA-B*58:01-positive individuals targeting
TW10 (n  5) compared to HLA-B*58:01-negative partici-
pants infected with viruses not carrying the B*57/B*58:01-
associated A146X and T242X mutations (n  12; 510 versus
316 cells l1; P  0.04) (see Fig. S1A in the supplemental
material), but no significant differences in plasma viral loads (me-
dian log viral load, 4.54 versus 4.38 copies ml1; P  0.96) (see
Fig. S1B). Taken together, these findings suggest that, despite
relatively rapid escape, the ability to target TW10 may be associ-
ated with slower disease progression.
Early escape may be facilitated by circulating compensatory
mutations. Secondary mutations upstream and downstream of
TW10 have been reported to partially restore viral fitness (4,
19, 21). Analysis of Gag sequences from the six HLA-B*58:
01-positive individuals revealed that at enrollment, five indi-
viduals already carried viral variants containing at least one
mutation that is either known, or strongly suspected, to com-
pensate for T242N-associated replicative fitness costs (Fig. 5).
Previous reports have detected a high frequency of the com-
pensatory mutation H219X in the absence of T242N, suggest-
ing that the compensatory mutation does not readily revert
following transmission to HLA-B*57/B*58:01-negative individ-
uals (19). All four of the study participants who developed
T242N (CAP217, CAP229, CAP239, and CAP274) had at least
one previously described compensatory mutation upstream of
the epitope (Fig. 5). Interestingly, CAP268, the one participant
who exhibited TW10-specific ELISpot responses but who did
not develop escape mutations within the epitope, had no up-
stream compensatory mutations at enrollment (1.8 months
postinfection). In this individual, the compensatory mutation




CAP217 02:02, 29:01 15:03, 58:01 02:10, 06:02
CAP229 01:23, 01:23 58:01, 58:01 06:02, 06:02
CAP239 01:23, 29:02 42:01, 58:01 06:02, 17:01
CAP268 02:05, 26:01 07:05, 58:01 07:01, 07:02
CAP270 03:01, 30:02 08:01, 58:01 07:01, 07:01
CAP274 02:01, 30:01 42:01, 58:01 03:02, 17:01
a PID, participant identification.
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FIG. 3. Alignment of Gag and Nef epitope sequences where additional CTL escape was detected and their flanking residues (one on either
























at I223 developed at 12.3 months postinfection and reached
fixation by 19.8 months postinfection (Fig. 5). However, the
T242N mutation had still not been detected by 31.4 months
postinfection. The appearance of the compensatory mutation
before the escape mutation may suggest an alternative escape
route whereby the fitness costs of escape are minimized by the
preceding compensatory mutation. In CAP239, an additional
potentially compensatory mutation (M228L) was detected at
18.2 months postinfection (Fig. 5).
TW10-associated compensatory mutations (H219X, I223X,
and M228X) were present at surprisingly high background
frequencies in our cohort (data not shown). Viruses infecting
25 out of the 36 individuals (69%) had at least one of the three
compensatory mutations (4 with H219X [11%], 23 with I223X
[64%], and 9 with M228X [25%]). Nine participants (25%)
harbored more than one compensatory mutation. To deter-
mine if the frequency of compensatory mutations was increas-
ing over time in subtype C infection, we compared transmitted
sequences from our study (which were sampled between 2004
and 2007; n  36) to sequences sampled from the same region
(South Africa) in chronic infections between 1997 and 2000
(www.hiv.lanl.gov; n  136). The total number of sequences
with any compensatory mutations in our study cohort was
higher than that in the reference data set, although this did not
reach statistical significance (69% versus 57%, respectively;
P  0.25) (see Table S3 in the supplemental material). Simi-
larly, there was no significant difference between the numbers
of sequences with variations at individual compensatory sites
(see Tables S3 and S4). However, there was a trend toward a
higher frequency of variation at position 223 in our study
cohort with respect to the background data set (64% versus
46%, respectively; P  0.09). We also examined reversion of
the compensatory mutations within the first 6 months in the 25
study participants who were infected with viruses carrying
these mutations at enrollment (see Table S5). Reversion was
observed at position 223 in only two individuals (CAP084 and
CAP256), indicating that compensatory mutations do not re-
vert readily upon transmission to new hosts (19). Interestingly,
both these individuals were dually infected. CAP084 was found
to be dually infected at the first available time point, while
CAP256 was superinfected with a second strain which was de-
tected at 3 months postinfection (25, 33). The high background
prevalence of TW10-associated compensatory mutations in the
study population has implications for the South African HIV
epidemic. Specifically, these mutations may increase the rate at
which viruses are able to escape TW10-targeted CTL responses
following their transmission to HLA-B*58:01-positive individuals.
DISCUSSION
The favorable disease outcome associated with HLA-B*58:01
has been attributed to strong CTL responses targeting the
FIG. 4. CD4 count and viral load comparisons between B*58:01-positive and B*58:01-negative individuals. (A and B) CD4 cell count
(A) and viral load (B) comparisons between HLA-B*58:01-positive study participants who developed the T242N mutation (B*58:01/T242X;
n  4) and the HLA-B*58:01-negative individuals who were not infected with viruses carrying B*57B*58:01-associated A146X and T242X
mutations (B*58:01/T242X/A146X; n  17) at 12 months postinfection. (C and D) CD4 cell count (C) and viral load (D) comparisons
between HLA-B*58:01-positive study participants who had ELISpot responses to the TW10 epitope (B*58:01/TW10; n  5) and HLA-B*58:
01-negative individuals who were not infected with viruses carrying B*57B*58:01-associated A146X and T242X mutations (B*58:01/T242X/
A146X; n  17) at 12 months postinfection. The CD4 counts and viral loads were calculated as the mean of three measurements taken at time
points closest to 12 months postinfection (range, 9 to 16 months).
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FIG. 5. Alignment of Gag p24 sequences surrounding the TW10 epitope (boxed) determined from clones sampled from the six HLA-B*58:
01-positive study participants. Indicated in yellow are the sites of previously described T242N compensatory mutations upstream of the TW10
epitope. The gray highlighting indicates minority variants. The Cyp A binding loop is underlined. The sequences are aligned to the subtype C
consensus p24 sequence, and numbering is according to the HXB reference sequence.
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functionally and structurally constrained p24Gag protein and to
mutational escape in this region resulting in viral variants with
reduced replicative capacity (9, 19, 21). However, possession of
HLA-B*58:01 does not guarantee slower disease progression,
and we were therefore interested in identifying immunological
and virological correlates of these differences.
Our data provide evidence as to how TW10-specific CTL
responses influence disease progression in HLA-B*58:01-pos-
itive individuals. Whereas the absence of TW10-specific re-
sponses was associated with high viral loads, the presence of
sustained TW10-specific responses in the absence of escape
was associated with better control of viremia. Individuals with
TW10-specific responses and who harbored viruses with known
escape mutations had typical viral loads. From the perspective
of CD4 counts, our study also provides some insight.
CAP270, who did not exhibit TW10-specific responses, had low
CD4 counts at 12 months postinfection (Fig. 2B). The ab-
sence of escape in TW10 despite consistent targeting may have
resulted in intermediate CD4 counts in this individual,
whereas individuals whose viruses escaped in TW10 under
consistent selection pressure had higher CD4 counts. Although
it is difficult to draw broad conclusions, the data support an
important role for TW10 targeting in B*58:01-mediated con-
trol of subtype C infection. Even though the HLA-B*58:01
allele was not broadly associated with lower viral loads, its
association with better preservation of CD4 cell counts may
provide long-term clinical advantages to infected individuals
(11, 23, 28). HLA-B*58:01-positive individuals who acquired
the T242N mutation within TW10 maintained higher CD4
cell counts up to 3 years postinfection.
The current study had the advantage of monitoring infected
individuals very close to their time of infection, enabling the
determination of mutational dynamics within immunodomi-
nant epitopes. Escape from the immunodominant TW10
epitope was rapid, with escape mutations emerging as early as
2 weeks postinfection, confirming strong selection pressures on
the virus exerted by HLA-B*58:01. In all cases, emergence of
T242N was preceded by another mutation within the epitope
(Fig. 1). This may suggest that (i) the route to escape is via
intermediate mutations; (ii) the T242N mutation, being at the
HLA binding site, provides the best selective advantage to the
virus; and/or (iii) the T242N mutation incurs a lower replica-
tive fitness cost than do the other mutations observed in the
epitope. The fact that all the variants detected prior to the
emergence of the T242N mutation are only rarely found in
circulating subtype C sequences (I243, 0%; H244, 0.24%; P244,
0%; T244, 0%; E246, 0%; V247, 7.26%; T248, 10.65%; Q248,
1.21%: www.hiv.lanl.gov) is consistent with the notion that they
are escape intermediates and that, compared to the TW10
mutation, they provide inferior selective advantages with re-
spect to balancing the demands of CTL escape fitness costs.
In CAP268, despite strong TW10-specific CTL responses
and selection of an upstream compensatory mutation at Gag
codon 223, no escape mutations occurred within TW10 up to
31.4 months postinfection. Although the lack of escape in
CAP268 could have been due to the lack of preexisting com-
pensatory mutations, it is possible that the M250I mutation
may have prevented TW10 escape due to fitness constraints, as
it tends to be mutually exclusive with the T242N mutation (21).
It is unlikely that the M250I mutation is a processing escape
mutation, as previously suggested (21), as CAP268 displayed a
strong ELISpot response to the TW10 epitope in the presence
of the mutation. If the autologous virus had escaped through
the M250I processing mutation, then TW10-specific CTL re-
sponses would have waned.
The other individual who did not develop escape muta-
tions within TW10, CAP270, also did not show any detect-
able responses to this epitope. This individual had a very
high viral load and a low CD4 count at 12 months postin-
fection (1,680,000 RNA copies ml1 and 255 cells l1, re-
spectively) and was classified as a rapid progressor. This sup-
ports previous reports suggesting that control of viral
replication by HLA-B*57/B*58:01-positive individuals is pri-
marily through immune targeting of the functionally and struc-
turally constrained TW10 epitope (14, 18). The reason for the
lack of TW10 responses in CAP270 is unclear. However, it is
possible that host factors associated with epitope processing or
presentation may influence epitope targeting and disease pro-
gression. Further characterization of the differences between
HLA-B*57/B*5801-positive individuals to distinguish TW10
responders from nonresponders may unravel the mechanisms
behind effective control of viremia. A recent study by Dinges et
al. reported that HLA-B*57/B*58:01 individuals who lacked
responses to the conserved epitopes had higher plasma viral
loads (10), suggesting that it is the precise genomic region
targeted rather than the allele per se that is predictive of dis-
ease progression. Here we show that specific targeting of the
highly conserved TW10 epitope in B*58:01-positive individuals
contributes to this association. Our study further illustrates
that escape patterns may contribute to disease progression.
Escape mutations arising in other B*58:01-restricted Gag
and Nef epitopes (other than TW10) were not obviously asso-
ciated with differences in disease progression, although re-
sponses to these epitopes may still have had subtle influences.
It is noteworthy that only one HLA-B*58:01-positive subject
(CAP268) targeted an additional B*57/B*58:01-restricted im-
munodominant epitope in p24Gag (KF11) with no evidence of
escape in this epitope, suggesting that additional targeting of a
p24 epitope may have contributed to the low viral load ob-
served in this individual. The absence of responses targeting
other p24 immunodominant epitopes (namely, ISW9, KF11,
and QW9) in the remaining B*58:01-positive individuals may
be due to the observed hierarchy of B*58:01 responses in
subtype C infection, where TW10 represents the primary target
during early infection and while other epitopes are targeted
only later (15).
Early CTL escape in the TW10 was likely facilitated by the
preexistence of compensatory mutations in the transmitted
viruses. The early escape, due to the preexistence of compen-
satory mutations, enables HIV to evade immune recognition at
a low fitness cost. This may result in high viral loads at set
point, causing rapid disease progression. Notably, the high
frequency of detection of compensatory mutations in the cir-
culating viruses compared to viruses sampled historically from
the same region suggests that their background frequencies are
increasing, possibly foreshadowing a diminishing protective ef-
fect of the B*57/B*58:01 alleles in this population over time.
Although our study identifies associations between disease
progression and virological and immunological factors, it has
several limitations. Other factors such as host genetics which
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may have influenced disease progression were not examined
here. While we examined immune responses to all HIV-1 pro-
teins, we examined sequences only from Gag and Nef. It is
conceivable that unstudied escape mutations elsewhere in the
genome could have contributed to disease progression. Our
reason for focusing on Gag and Nef was their immunodomi-
nance and the fact that responses targeting Gag have in par-
ticular been associated with better disease outcomes (16, 18).
In addition, we considered only IFN- secretion, measured via
ELISpot assay, as an indicator of HIV-1-specific responses.
Not all activated HIV-1-responsive CD8 T cells produce
IFN-, however; thus, the HIV-specific responses measured
here are most likely an underestimation of the total responses
observed in vivo. Also, consensus subtype C peptides were used
in the ELISpot assays, possibly resulting in a further underes-
timation of responses due to mismatches between the autolo-
gous and consensus peptide sequences. Lastly, we examined
only six B*58:01-expressing individuals, and it would therefore
be of interested to confirm these findings in a larger data set.
Our study shows that the B*58:01 allele plays a key role in
disease progression and that this influence is largely attribut-
able to the targeting of constrained epitopes, TW10 in this
case. Our results also suggest that the presence of high fre-
quencies of compensatory mutations at the population level
may limit the protective value of B*58:01. Finally, our study
further emphasizes the notion that the design of HIV vaccine
immunogens should take into consideration predictable pat-
terns of immune evasion.
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